Featured content
Article
From leaderboards to lab notebooks: AI designs reach preclinical testing
For years, AI drug discovery has been judged on benchmark performance. Now, a set of studies shows what happens when those designs are made and tested in preclinical settings.
ArticleVariant or viable target? How resolving complex genomic regions is reshaping rare disease therapeutics
Dr Aaron Wenger reveals how improvements in long-read sequencing technology is enabling the elucidation of complex disease mechanisms for targeted and effective treatments for rare diseases.
ArticleThe future of academic core labs: scaling operational excellence without increasing staff
The grounds have shifted the foundations of academic core facilities and the current climate demands their strategic agility in order to thrive. Boyd Butler at Molecular Devices reveals how these labs can capitalise on this opportunity to increase value and efficiency.
ArticleAnalytica 2026: Connecting data across drug discovery workflows
Drug discovery is generating more data than ever, but the challenge is making sure that data is reliable, connected and usable. At Analytica 2026 in Munich, Drug Target Review spoke with technology developers and industry leaders across the exhibition floor to understand how these challenges are being addressed.
Opinion and interviews
Computational design drives new generation of synthetic promoters
Designing gene control from scratch is becoming possible. SynGenSys is using computational design to create synthetic promoters for advanced therapies.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
Webinars
- Previous
- Next
